As an integral step in the oncology drug discovery process, cell line derived xenograft models provide key decision-making information to allow an agent to move forward, and clients to advance their preclinical development programs in a timely and cost-effective manner.
Crown Bioscience has established multiple in vivo assay systems to evaluate novel anticancer compounds, with each assay specifically designed to understand a drug's mechanism of action, or an individual agent property.
Working with Crown Bioscience gives you access to XenoBase®, our online collated database of well-characterized cell lines and cell line derived xenograft models, which includes standard of care and RNAseq data to enable easy model selection.
Over 200 validated and well-characterized cell line derived xenografts covering subcutaneous, orthotopic, and systemic models.
The collection includes metastasis models (spontaneous and experimental) covering major cancer types such as:
These unique models are derived from our HuPrime® patient-derived xenograft (PDX) models, via cell lines. Many of these models harbor mutations of novel therapeutic targets, such as:
PrimeXeno models are ideal for early stage drug discovery, where a robust system is needed to screen large numbers of compounds in assays such as PK/PD analysis.
Nude rat xenograft models are recognized as an attractive option compared to mouse models, because a compounds’ PK properties are typically closer to that observed in humans.
Crown Bioscience has validated both subcutaneous and orthotopic nude rat xenograft models, covering:
Crown Bioscience provides bioluminescent subcutaneous, orthotopic, and metastatic cell line derived xenograft models for optical imaging.
These models provide valuable disease information at different cancer stages, through orthotopic models mimicking primary lesions, to the imaging of both spontaneous and experimental metastases to replicate progression to late stage disease.
Bioluminescent PC-3M-luc Orthotopic Prostate Cancer
Model Tumor Growth Inhibition Following Docetaxel Treatment